Clinical trials: Buprenorphine
Addiction
Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain.
- Trial name
- NCT05076370
- Testing
- CBD Day 1, CBD Day 2, CBD Day 3
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yale University
Spinal Disorder
An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders
The purpose of this study is to assess the pain reduction rate after 8 weeks treatment of NORSPAN® from baseline. And secondary purpose are: pain reduction rate after 4 weeks treatment from baseline(week 0) the EQ-5D, the pain…
- Trial name
- NOBLE (NCT01818700)
- Testing
- Buprenorphine
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Mundipharma Korea Ltd
Opioid-use Disorder
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard…
- Trial name
- NCT04893525
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in Canada
- Volunteers
- 658 people
- Sponsor
- University of British Columbia
Opioid Use Disorder
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
The purpose of this study is to evaluate the efficacy; safety and tolerability of ASP8062 compared with placebo ASP8062 as add-on therapy to buprenorphine/naloxone.
- Trial name
- NCT05062577
- Testing
- ASP8062, buprenorphine/naloxone
- Sponsor
- Astellas Pharma Global Development, Inc.
Prescription Opioid Dependence
Effective Treatment for Prescription Opioid Abuse
There has been an alarming increase in abuse of prescription opioids in recent years. This project aims to develop an effective outpatient treatment for prescription opioid (PO) abuse that combines an intensive behavioral therapy…
- Trial name
- NCT00719095
- Testing
- buprenorphine taper followed by naltrexone maintenance, Behavioral therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Vermont Medical Center
Opioid-Related Disorders, Substance-Related Disorders
Buprenorphine Maintenance for Opiate Dependence - 6
The purpose of this study is to determine the efficacy of buprenorphine as a substitution pharmacotherapy for opiate dependence.
- Trial name
- NCT00000357
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Dependence, on Agonist Therapy
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent…
- Trial name
- NCT01903005
- Testing
- Higher bioavailability BNX sublingual tablets
- Where
- 28 sites in United States
- Volunteers
- 668 people
- Sponsor
- Orexo AB
Opioid Use Disorder, Peer Recovery Supporters
Peer Recovery Support for Opioid Use Disorder Treatment Retention
The goal of this clinical trial is to learn whether adding peer recovery support services to standard opioid use disorder (OUD) treatment in primary care helps patients stay in treatment longer.
- Conditions
- Opioid Use Disorder, Peer Recovery Supporters, Peer Recovery Coaching, Primary Care
- Trial name
- NCT07620171
- Testing
- Peer Support
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections, Opioid Use Disorder
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial…
- Conditions
- HIV Infections, Opioid Use Disorder, Incarceration; Lens
- Trial name
- NOTRE (NCT06854029)
- Testing
- Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Duke University
Opioid Use Disorder
Virginia Opioid Treatment-Emergency Department
The current study seeks to test the feasibility of an alternative treatment for patients with opioid use disorder who present to the emergency department seeking treatment or with opioid withdrawal, which includes FDA approved…
- Trial name
- VOT-ED (NCT04523792)
- Testing
- SUBLOCADE
- Sponsor
- Virginia Commonwealth University
Opioid-use Disorder
Single Ascending Dose Study of ALA-1000
An open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of ALA-1000 in opioid-dependent subjects.
- Trial name
- NCT04122755
- Testing
- ALA-1000, buprenorphine sublingual film
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Alar Pharmaceuticals Inc.
Opioid Use Disorder, Opioid Dependence
Medication-Assisted Treatment for Youth With Substance Use Disorders
The purpose of this open-label pilot study is to determine the tolerability and applicability of outpatient long-acting injectable naltrexone (Vivitrol) treatment in individuals age 16-25 ("older youth") with opioid use disorder.
- Trial name
- NCT02593474
- Testing
- Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
Opioid-Use Disorder, Opioid Overdose
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
This pilot study will evaluate the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).
- Trial name
- FASTER-BUP (NCT04815590)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- BC Centre on Substance Use
Anesthesia, Local
Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain…
- Trial name
- NCT03117140
- Testing
- Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Melinda Seering
Opioid Use Disorder (OUD), Chronic Pain
Addiction Treatment in Primary Care Expansion
The Veterans Health Administration (VA) is a national leader in addressing the twin epidemics of chronic pain and opioid use, misuse, and opioid use disorder (OUD); but important challenges remain.
- Trial name
- APEX (NCT03547882)
- Where
- 2 sites in United States
- Sponsor
- VA Office of Research and Development
Opiate Dependence, Chronic Pain
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
This study is designed to develop an effective psychotherapy for chronic pain and opioid dependence.
- Trial name
- POD (NCT00634803)
- Testing
- CBT, Buprenorphine, Educational Counseling
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Yale University
Opioid Dependency, HIV Infections
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
The purpose of this study is to examine the interactions of buprenorphine-naloxone, a medication used to treat opiate (heroin or prescription narcotic) dependence, and medications used in the treatment of HIV disease including…
- Trial name
- NCT00877591
- Testing
- Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Opiate Dependence
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
A randomized clinical trial evaluating whether Behavioral Drug and HIV Risk Reduction Counseling (BDRC), abstinence-contingent take-home buprenorphine (ACB), or the combination of the two improve efficacy and cost-effectiveness…
- Trial name
- NCT00539123
- Testing
- behavioral drug and HIV risk reduction counseling (BDRC), abstinence-contingent buprenorphine (ACB)
- Where
- 2 sites in United States, Malaysia
- Volunteers
- 234 people
- Sponsor
- Yale University
Opioid Dependence
Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments
This study will compare the effects of brief strengths-based case management (SBCM) to the effects of screening, assessment and referral alone (SAR) in opioid-dependent patients.
- Trial name
- NCT02586896
- Testing
- Strengths-based Case Management (SBCM), Screening, Assessment, and Referral (SAR)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NYU Langone Health
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP